Torrent Pharmaceuticals Share Price in Focus After Q2 FY27 Earnings Results: Total Income Up 51.7% YoY

On October 23, 2026, Torrent Pharmaceuticals Limited released its consolidated financial results for the quarter and half-year ending September 30, 2026, as per the exchange filings.  

The company reported a significant increase in total income but faced a decline in net profit compared to the previous year. 

Torrent Pharmaceuticals Q2 FY27 Earnings Results 

In the September 2026 quarter, Torrent Pharmaceuticals' total income rose by 51.7% year-on-year to ₹4,969 crore, up from ₹3,275 crore in the same quarter of the previous year. Compared to the June 2026 quarter, this represents a 1.2% increase from ₹4,909 crore.  

However, the net profit for the quarter fell by 9.6% year-on-year to ₹534 crore, down from ₹591 crore a year ago, and decreased by 5.7% quarter-on-quarter from ₹566 crore. 

Half-Yearly Financial Overview 

For the half-year ending September 30, 2026, the company's total income increased by 54.0% year-on-year, reaching ₹9,878 crore compared to ₹6,416 crore in the corresponding period of the previous year.  

The net profit for this period was ₹1,100 crore, reflecting a 3.4% decrease from ₹1,139 crore in the previous year. 

Strategic Developments 

Torrent Pharmaceuticals successfully completed the amalgamation of J.B. Chemicals & Pharmaceuticals Limited, sanctioned by the National Company Law Tribunal on July 6, 2026. The appointed date for this transaction was January 21, 2026. Historical financial accounts were restated using pooling of interest accounting protocols. 

Operating Profit and Margins 

The consolidated operating EBITDA surged by 54% over the prior year to ₹1,666 crore, with an operating gross profit margin of 75.4%. The operational EBITDA margin was 33.5% before exceptional adjustments. 

Read More: Sapphire Foods India Share Price in Focus After Q2 FY27 Earnings Results: Total Income Up 19.1% YoY! 

Standalone Financials 

The standalone revenue from operations was ₹4,145 crore, with a net profit after tax of ₹498 crore. Standalone earnings before exceptional charges and tax provisions were ₹686 crore, with material input costs at ₹584 crore. 

Corporate Financial Position 

The total consolidated assets reached ₹44,615 crore, with long-term property assets valued at ₹4,407 crore. Goodwill balances remained at ₹3,990 crore, and short-term inventory was valued at ₹3,182 crore. 

Torrent Pharmaceuticals Share Price Performance 

As of October 23, 2026, at 3:30 PM, Torrent Pharmaceuticals share price on NSE was closed at ₹4,524.40, down by 1.97% from the previous closing price. 

Conclusion 

Torrent Pharmaceuticals reported a 51.7% YoY increase in total income to ₹4,969 crore for Q2 2026, while net profit decreased by 9.6% to ₹534 crore. The half-year income rose 54% YoY to ₹9,878 crore, with a 3.4% drop in net profit to ₹1,100 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.